Table 3.
Laboratory values at baseline and at end of follow-up period
| Median (IQR) | p-value | ||
|---|---|---|---|
| Laboratory parameter | |||
| Absolute CD4 Count (n = 38) | Baseline (cells/uL) | 323 (220 to 519) | |
| Follow up (cells/uL) | 397 (252 to 603) | ||
| Follow up Duration (Weeks) | 49 (44 to 52) | ||
| Change (cells/uL) | 31 (− 32 to + 141) | < 0.01b | |
| Glucose monitoring | |||
| Fasting blood glucose (n = 11) | Baseline (mmol/L) | 5.1 (4.9 to 5.7) | |
| Follow Up (mmol/L) | 5.2 (4.7 to 5.5) | ||
| Follow up Duration (Weeks) | 50 (46 to 52) | ||
| Change (mmol/L) | 0.3 (− 0.5 to + 0.4) | 0.654b | |
| HbA1c (n = 8) | Baseline (%) | 5.75 (5.55 to 6.5) | |
| Follow Up (%) | 5.85 (5.5 to 6.78) | ||
| Follow up Duration (Weeks) | 50 (40 to 58) | ||
| Absolute Change (%) | 0.05 (− 0.08 to + 0.2) | 0.288a | |
| Renal | |||
| eGFR (n = 139) | Baseline (ml/min/1.73m2) | 90 (78 to 104) | |
| Follow Up (ml/min/1.73m2) | 87 (76 to 99) | ||
| Follow up Duration (Weeks) | 49 (40 to 54) | ||
| Change (ml/min/1.73m2) | − 4 (− 14 to 5) | < 0.01b | |
| eCrCl (n = 139) | Baseline (ml/min) | 91 (76 to 106) | |
| Follow Up (ml/min) | 90 (76 to 106) | ||
| Follow up Duration (Weeks) | 49 (40 to 54) | ||
| Change (ml/min) | − 1 (− 9 to + 8) | 0.423a | |
| Lipids | |||
| TC (n = 38) | Baseline (mmol/L) | 5.1 (4.6 to 6.0) | |
| Follow Up (mmol/L) | 5.2 (4.4 to 5.8) | ||
| Follow up Duration (Weeks) | 51 (45 to 54) | ||
| Change (mmol/L) | 0.1 (− 1.1 to + 0.8) | 0.778b | |
| HDL-C (n = 38) | Baseline (mmol/L) | 1.0 (0.9 to 1.4) | |
| Follow Up (mmol/L) | 1.2 (0.9 to 1.3) | ||
| Follow up Duration (Weeks) | 50 (45 to 54) | ||
| Change (mmol/L) | 0 (− 0.2 to + 0.2) | 0.762b | |
| dC LDL-C (n = 38) | Baseline (mmol/L) | 2.9 (2.6 to 3.6) | |
| Follow Up (mmol/L) | 2.8 (2.4 to 3.5) | ||
| Follow up Duration (Weeks) | 51 (45 to 54) | ||
| Change (mmol/L) | − 0.1 (− 0.5 to + 0.5) | 0.817b | |
| LDL-C (n = 35) | Baseline (mmol/L) | 3.1 (2.6 to 3.7) | |
| Follow Up (mmol/L) | 3.1 (2.7 to 3.7) | ||
| Follow up Duration (Weeks) | 51 (45 to 54) | ||
| Change (mmol/L) | 0.1 (− 0.6 to + 0.7) | 0.972b | |
| Liver | |||
| ALT (n = 117) | Baseline (U/L) | 28 (21 to 44.5) | |
| Follow Up (U/L) | 22 (16 to 30) | ||
| Follow up Duration (Weeks) | 48 (41 to 52) | ||
| Change (U/L) | − 6 (− 11 to + 0) | < 0.001a | |
eGFR Estimated glomerular filtration rate, eCrCl Estimated creatinine clearance, TC Total cholesterol, HDL-C High density lipoprotein cholesterol, dC LDL-C Low density lipoprotein cholesterol estimated with the de Cordova equation. [21], LDL-C Low density lipoprotein cholesterol, ALT Alanine transaminase
aWilcoxon signed rank test
bPaired samples t-test